ASH 2023 | CLL highlights from ASH 2023: the FLAIR study
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the highlights in the space of chronic lymphocytic leukemia (CLL) at the ASH 2023 meeting, focusing on the FLAIR study (ISRCTN01844152) of ibrutinib plus venetoclax with MRD-guided duration of treatment compared to FCR in treatment-naïve CLL. Although progress has been made in the CLL space, Dr Davids highlights some questions which, at present, remain unanswered. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Research to Practice, Mingsight Pharmaceuticals, Merck, Janssen, Genentech, Eli Lilly, Curio Science, BMS, BeiGene, Aptitude Health, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, Secura Bio, TG Therapeutics, Takeda, ONO Pharmaceuticals, AbbVie
Research Funding: Genentech, Ascentage Pharma, AstraZeneca, Surface Oncology, Novartis, TG Therapeutics, MEI Pharma, AbbVie
